Inhibition of RAC attenuates Adriamycin-induced podocyte injury

Area of Science:

• Nephrology
• Molecular Biology
• Genomics

Background:

• Minimal Change Disease (MCD) is a primary cause of nephrotic syndrome in children, often requiring prolonged immunosuppression.
• Frequent relapses and multi-drug resistance can lead to progressive kidney damage, specifically Focal Segmental Glomerulosclerosis (FSGS).
• Podocyte injury is a critical factor in the pathogenesis of MCD and FSGS.

Purpose of the Study:

• To identify novel therapeutic targets for podocyte injury in MCD and FSGS.
• To analyze differentially expressed genes (DEGs) in kidney samples from MCD patients and healthy controls.
• To investigate the therapeutic potential of targeting specific genes involved in podocyte injury.

Main Methods:

• Microarray data analysis of glomerular mRNA from MCD patients and healthy donors.
• Construction of a protein-protein interaction (PPI) network using STRING database.
• Identification and validation of hub genes using cytoHubba and qRT-PCR.
• In vitro studies using Adriamycin (ADR)-induced human podocytes (HPCs) to assess RAC2 downregulation and EHT-1864 efficacy.

Main Results:

• Analysis identified differentially expressed genes (DEGs) and constructed a PPI network.
• RAC2 was identified as a key hub gene and a potential therapeutic target.
• Downregulation of RAC2 attenuated Adriamycin-induced podocyte injury.
• EHT-1864, a small molecule inhibitor of the RAC family, demonstrated superior efficacy in protecting podocytes compared to RAC2 silencing.

Conclusions:

• The study identified RAC2 as a potential therapeutic target for podocyte injury in MCD and FSGS.
• EHT-1864 shows promise as a novel molecular drug candidate for treating MCD and FSGS by targeting the RAC family.
• Further investigation of EHT-1864 is warranted for clinical application in patients with these kidney diseases.